The Oxford-AstraZeneca COVID-19 vaccine has 3 key advantages despite lower efficacy rate
The United Kingdom on Wednesday authorized the COVID-19 vaccine developed by the University of Oxford and AstraZeneca for use, joining the Pfizer-BioNTech shot, which has already been rolled out, as another tool in the country's massive vaccination drive. U.K. Health Secretary Matt Hanock said enough doses of both vaccines are on order to give the entire population two jabs, and he's "highly confident that we can get enough vulnerable people vaccinated by the spring that we can now see our route out of this pandemic."
Skeptics may want some caveats attached to that statement since the Oxford-AstraZenca vaccine had some mixed results in clinical trials. Data revealed earlier this month showed it was 62 percent effective in preventing symptomatic COVID-19 infections, which is not as high as the roughly 95 percent efficacy rate attributed to the Pfizer-BioNTech and Moderna candidates.
But the Oxford-AstraZeneca shot is nevertheless considered safe, and none of the volunteers developed a severe infection or were hospitalized, key metrics in determining the success of a vaccine. It also comes with a few key logistical advantages that could be a game-changer. It's cheap to produce, and unlike the Pfizer-BioNTech vaccine doesn't require ultra-cold temperatures for storage, which will make vaccine distribution easier, especially to rural communities. Finally, the gap between the first and second dose of the vaccine can be as long as 12 weeks, which means more people in the U.K. can receive an initial dose at an earlier stage, giving them some form of protection before the second. Read more at Reuters and The Wall Street Journal.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Why au pairs might become a thing of the past
Under The Radar Brexit and wage ruling are threatening the 'mutually beneficial arrangement'
By Chas Newkey-Burden, The Week UK Published
-
'A direct, protracted war with Israel is not something Iran is equipped to fight'
Instant Opinion Opinion, comment and editorials of the day
By Harold Maass, The Week US Published
-
Today's political cartoons - April 17, 2024
Cartoons Wednesday's cartoons - political anxiety, jury sorting hat, and more
By The Week US Published
-
Texas dairy worker gets bird flu from infected cow
Speed Read The virus has been spreading among cattle in Texas, Kansas, Michigan and New Mexico
By Peter Weber, The Week US Published
-
Dengue hits the Americas hard and early
Speed Read Puerto Rico has declared an epidemic as dengue cases surge
By Peter Weber, The Week US Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
Seattle Children's Hospital sues Texas over 'sham' demand for transgender medical records
Speed Read Texas Attorney General Ken Paxton subpoenaed records of any Texan who received gender-affirming care at the Washington hospital
By Peter Weber, The Week US Published
-
Afghanistan has a growing female suicide problem
Speed Read The Taliban has steadily whittled away women's and girls' rights in Afghanistan over the past 2 years, prompting a surge in depression and suicide
By Peter Weber, The Week US Published
-
US life expectancy rose in 2022 but not to pre-pandemic levels
Speed Read Life expectancy is slowly crawling back up
By Devika Rao, The Week US Published
-
Vallance diaries: Boris Johnson 'bamboozled' by Covid science
Speed Read Then PM struggled to get his head around key terms and stats, chief scientific advisor claims
By The Week UK Published
-
An increasing number of dog owners are 'vaccine hesitant' about rabies
Speed Read A new survey points to canine vaccine hesitancy
By Devika Rao, The Week US Published